Description of the medicine: Pergolide (Pergolide)
8B - [(Methylthio) methyl] -6-propylene ergoline monomethanesulfonate (mesylate).
Synonym: Permax, Permax.
On chemical structure belongs to the group of ergolines and has elements of structural similarity with ergot alkaloids (see. Dihydroergotamine) and bromocriptine (see).
Like bromocriptine, it is a stimulant of the D1- and D2-dopamine receptors of the brain nigrostriatal system; inhibits prolactin secretion.
It is well absorbed in the digestive tract; excreted mostly by the kidneys in the form of metabolites.
It is used mainly as an anti-Parkinsonian drug.
Assign inside, starting with 0.05 mg once a day, then (after 2-3 days) the dose is gradually increased by 0.1-0.25 mg per day to an average daily dose of 3 mg (in 3 doses).
A combination with levodopa preparations is acceptable (with a decrease in the dose of the latter).
When using the drug are possible: arterial hypotension (especially in the first days of therapy), arrhythmias, dizziness, sleep disturbances, dyskinesia, peripheral edema, etc.
With caution is prescribed for arterial hypotension, arrhythmias, dyskinesias associated with the administration of levodopa.
The drug should not be taken while breastfeeding (penetrates the mother’s milk); during pregnancy, it is permissible to use it under strict indications with caution.
Enhances the effects (including side effects) of levodopa; dopamine antagonists (antipsychotics, metoclopramide) can reduce the antiparkinsonian effect of pergolide.
Release form: tablets on 0,00005; 0.000025 and 0.001 g (0.05; 0.25 and 1 mg) (N.10, 30, 100).
Storage: List B.